BR112023024627A2 - Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas - Google Patents

Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas

Info

Publication number
BR112023024627A2
BR112023024627A2 BR112023024627A BR112023024627A BR112023024627A2 BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2 BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
treatment methods
domains
active kidney
factor
Prior art date
Application number
BR112023024627A
Other languages
English (en)
Portuguese (pt)
Inventor
A Andrien Bruce Jr
William Hunter Jeffrey
Julian Chandler
Keith Bouchard
Sung-Kwon Kim
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Priority claimed from PCT/US2022/030658 external-priority patent/WO2022251168A1/en
Publication of BR112023024627A2 publication Critical patent/BR112023024627A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
BR112023024627A 2021-05-25 2022-05-24 Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas BR112023024627A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192835P 2021-05-25 2021-05-25
PCT/US2022/030658 WO2022251168A1 (en) 2021-05-25 2022-05-24 Kidney active fusion proteins and methods of treatment using the same

Publications (1)

Publication Number Publication Date
BR112023024627A2 true BR112023024627A2 (pt) 2024-02-20

Family

ID=84178944

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024627A BR112023024627A2 (pt) 2021-05-25 2022-05-24 Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas

Country Status (10)

Country Link
US (1) US20240262877A1 (https=)
EP (1) EP4347666A4 (https=)
JP (2) JP2024520421A (https=)
KR (1) KR20240013770A (https=)
CN (1) CN117396519A (https=)
AU (1) AU2022283254A1 (https=)
BR (1) BR112023024627A2 (https=)
CA (1) CA3177162A1 (https=)
IL (1) IL308754A (https=)
MX (1) MX2023014037A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301713A (en) * 2020-10-05 2023-05-01 Alexion Pharma Inc Methods for treating dermatomyositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218409A2 (en) * 2000-03-13 2002-07-03 St. Vincent's Hospital (Melbourne) Limited Factor-h related protein 5 (fhr-5) and antibodies thereto
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US9815876B2 (en) * 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
CA2920293A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Also Published As

Publication number Publication date
JP2025116068A (ja) 2025-08-07
JP2024520421A (ja) 2024-05-24
IL308754A (en) 2024-01-01
EP4347666A1 (en) 2024-04-10
CN117396519A (zh) 2024-01-12
EP4347666A4 (en) 2025-07-16
AU2022283254A9 (en) 2023-12-07
KR20240013770A (ko) 2024-01-30
US20240262877A1 (en) 2024-08-08
CA3177162A1 (en) 2022-11-25
AU2022283254A1 (en) 2023-11-30
MX2023014037A (es) 2024-01-15

Similar Documents

Publication Publication Date Title
CY1122686T1 (el) Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
ATE476654T1 (de) Plattform für protein-profiling
ATE251942T1 (de) Stapelbare statische mischelemente
BRPI0410876A (pt) molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
de Roodt et al. Cross-reactivity and heterologous neutralization of crotaline antivenoms used in Argentina
SE8902532D0 (sv) Bestaemning av plasmaproteiner
BRPI0414215A (pt) tienopirazóis
BR112023024627A2 (pt) Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas
DE60239467D1 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
DE69913325D1 (de) Nephrin gen und protein
ATE466870T1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
EP1549672A4 (en) ABLATED SLAM DEPENDENT ENTRY
ATE349702T1 (de) Nachweis und quantifizierung von cripto-1
CO2023015999A2 (es) Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas
Gilbert et al. Purification of fibrinogen and virus removal using preparative electrophoresis
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE529536T1 (de) Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen